Enhanced antitumor reactivity with tumor regression in 75% of treated mice was observed for the HER2-DC1 i.t. combined with anti-HER2 antibodies trastuzumab and pertuzumab treatment when compared with paclitaxel combined with anti-HER2 antibodies trastuzumab and pertuzumab (Figure 7C, D). This evidence concerns the gene ERBB2 and neoplasm.